Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Monosialotetrahexosylganglioside (GM1) – Heat-labile enterotoxin (LT) complex is a molecular assembly formed when the heat-labile enterotoxin produced by Enterotoxigenic Escherichia coli (ETEC) binds to the GM1 ganglioside on the surface of host intestinal epithelial cells (Merritt et al., 1994, Protein Science). The LT holotoxin is an AB5-type protein complex comprising an enzymatic A subunit and a pentameric B subunit (LTB), the latter of which possesses high affinity for the carbohydrate moiety of GM1 (Sixma et al., 1991, Nature). This binding event is the prerequisite for toxin internalization via receptor-mediated endocytosis, leading to the retrograde transport of the A subunit to the endoplasmic reticulum and eventually the cytosol. Once in the cytosol, the A subunit ADP-ribosylates the Gs alpha subunit of adenylate cyclase, causing constitutive activation and increased levels of cyclic AMP (cAMP), which triggers chloride secretion and inhibits sodium absorption, resulting in severe watery diarrhea (Clements et al., 1980, Infection and Immunity). As the primary gateway for ETEC pathogenesis, this complex is a major focus for therapeutic intervention, including the development of oral vaccines like Dukoral and ETVAX that induce neutralizing antibodies against the B subunit (World Health Organization, 2020). Additionally, small-molecule inhibitors and multivalent ligands are being researched to competitively block the GM1-LT interaction to prevent infection (Pickens et al., 2002, Chemistry & Biology).
Competitive inhibition of the B-subunit pentamer binding to the GM1 ganglioside receptor on the host cell surface, thereby preventing toxin internalization and subsequent activation of adenylate cyclase.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Monosialotetrahexosylganglioside (GM1) – Heat-labile enterotoxin (LT) complex (GM1-LT complex).